SCHEMBL4012419

SCHEMBL4012419

N#Cc1cnn(-c2ccc(NC(=O)OCc3ccccc3)cc2F)c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.45
MGLL Q99685 3/20 0.44
POLB P06746 1/20 0.43
TP53 P04637 2/20 0.43
MAPT P10636 2/20 0.43
SCD O00767 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.43
ATM Q13315 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ROCK2 O75116 3/20 0.42
ENPP2 Q13822 1/20 0.41
TDO2 P48775 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7843556 0.85 MGLL (0.47) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL3753454 0.85 MGLL (0.49) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL4011732 0.83 MGLL (0.47) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL7844206 0.83 MGLL (0.47) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL3759889 0.81 NAMPT (0.48) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL15710402 0.80 MGLL (0.45) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL7830249 0.80 MGLL (0.52) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL13054799 0.80 MGLL (0.44) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL13054802 0.79 PTGDR2 (0.44) PTGDR2MGLLPOLBTP53MAPT
SCHEMBL7831820 0.79 BLM (0.51) PTGDR2MGLLPOLBTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473699-B2 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents ASTRAZENECA AB (SE) 2009-01-06 US disclosed
US-7473699-B2 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents ASTRAZENECA AB (SE) 2009-01-06 US disclosed
US-20050119292-A1 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents ASTRAZENECA AB (SE) 2005-06-02 US disclosed
EP-1497286-A1 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Astrazeneca AB (SE) 2005-01-19 EP disclosed
WO-2003072575-A1 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119292-A1 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents H1-0, NGLY1, H1-5 PTGDR2 1837/4885MGLL 1904/4885POLB 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.